Maci 3CM x 5CM implant sheets
Ended Awarded Last action
- Contract number
- SPE2DR26FKAR8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $63,176
Award facts
- Contract value 100% obligated
- $63,175.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $63,175.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for MACI 3cm x 5cm implant sheets. The delivery order, issued on December 31, 2025, with an ultimate completion date of January 23, 2026, carries no set-aside designation, indicating the award was made through open competition. DMS Pharmaceutical Group will deliver these specialty surgical implants to support Department of Defense medical supply requirements, leveraging its established capabilities as a critical supplier within the federal pharmaceutical and medical consumables supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical and medical product support to military healthcare facilities worldwide. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, positions DMS Pharmaceutical Group as a regional prime vendor contractor authorized to provide firm fixed-price delivery orders for branded and generic pharmaceuticals, biologics, medical consumables, and specialty surgical products. The company's substantial federal contracting activity and diverse product portfolio, which includes high-value specialty items such as oncology treatments and biologic agents, demonstrate its capability to fulfill the specialized pharmaceutical and medical supply requirements of the Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FKAR8?
SPE2DR26FKAR8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 31, 2025.
How much is contract SPE2DR26FKAR8 worth?
The government has obligated $63,176 on SPE2DR26FKAR8.
Is contract SPE2DR26FKAR8 an order under another contract?
Yes. SPE2DR26FKAR8 is a delivery order under SPE2DR25D9365, an indefinite delivery contract.
Was contract SPE2DR26FKAR8 competed?
The extent of competition for SPE2DR26FKAR8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award